

Generic Name: Clopidogrel

Type: Platelet receptor antagonist

- Action:**
- Clopidogrel is a specific and potent inhibitor of platelet aggregation and limits propagation of the thrombus by selectively inhibiting the binding of ADP to its platelet receptor
 - Clopidogrel is absorbed from the stomach and upper small bowel and begins to inhibit platelet function within 30 minutes

Route	Onset	Peak	Duration
PO	2-10 minutes	N/A	3-6 hours

Use: • C13 - Cardiac Reperfusion - Prehospital Thrombolysis (PHT)

- Adverse Effects:**
- Allergic reactions (e.g. asthma, angioneurotic oedema, rhinitis, urticaria, laryngeal oedema and shock) - Always check for history of previous reaction
 - Aggravation of any bleeding tendency
 - Gastric irritation (unlikely to be significant with current dose)
 - Bleeding may take longer to stop

- Contraindications:**
- **Active, suspected or known bleeding tendency**
 - **Allergy or hypersensitivity to clopidogrel**
 - **Any exclusion per the Pre-hospital Thrombolysis Checklist (R21)**
 - **Patients < 18 years of age**
 - **Pregnancy or breast feeding**

Preparation: • 75mg tablet

- Notes**
- Warfarin and regular daily use of clopidogrel is not a contraindication to clopidogrel administration

Dose					
Patient	Clinical LVL	Route	Initial Dose	Repeat	Max Total Dose
CARDIAC REPERFUSION - PREHOSPITAL THROMBOLYSIS (PHT)					
≥ 18 - < 75	P1+	PO	300mg	Nil	300mg
≥ 75	P1+	PO	75mg	Nil	75mg

Clinical Level Key: ¹- Geographical Areas—Auth Paramedics Only, ²- Under approved circumstances, ³- ALS & ICP who have completed P1 training, ⁴- P1 paramedics on completion of training package



Approved by: Executive Director Clinical Systems Integration

Revised: July 2018

Page 1 of 1

Maintained by: Clinical Systems Integration

2020 Protocol and Pharmacology